Oncology (all articles)
Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care.
9 Nov, 2021 | 01:44h | UTCRelated:
2 Case Series and Guidance | Lymphadenopathy in COVID-19 Vaccine Recipients
Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors.
9 Nov, 2021 | 01:04h | UTC
Commentary on Twitter
#Neuroendocrine tumors are heterogeneous with a complex treatment landscape. This #JCOOP Clinical Review discusses optimal management of #NET and key patient/tumor characteristics that can guide treatment selection https://t.co/zZF36E93w8 pic.twitter.com/2xqwOlwIvw
— Journal of Clinical Oncology (@JCO_ASCO) October 28, 2021
FDA Pooled Analysis: Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant.
9 Nov, 2021 | 01:05h | UTCOverall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
A pooled analysis of phase III trials of fulvestrant plus either CDK4/6 inh or placebo in pts with HR+/HER2- advanced-stage #breastcancer shows an mOS benefit of 7.1 months (over a mFU of 43.7 months) favouring CDK4/6i (HR 0.77, 95% CI 0.68–0.88): https://t.co/ZMa0J8gS8Q #bcsm
— NatureRevClinOncol (@NatRevClinOncol) October 21, 2021
M-A: Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer.
7 Nov, 2021 | 20:07h | UTC
Cluster RCT: In older adults with advanced cancer, a geriatric assessment program reduced the toxic effects of cancer treatment.
5 Nov, 2021 | 09:48h | UTCRelated:
Perspective: A Cancer Care Approach Tailored to The Elderly May Have Better Results
Commentary from the author on Twitter (thread – click for more)
https://twitter.com/rochgerionc/status/1456046017766375425
CDC Guidance: Immunocompromised may need a fourth Covid-19 shot.
4 Nov, 2021 | 10:06h | UTCCommentaries:
Immunocompromised may need a fourth Covid-19 shot, CDC says – CNN
Some immunocompromised people can receive a 4th Covid shot, CDC says – NBC News
A national HPV vaccination program in England was associated with an estimated reduction in cervical cancer rates of 87% for those offered the vaccine at age 12–13 years.
4 Nov, 2021 | 09:58h | UTCRelated:
CDC: 92% of Human Papillomavirus–Attributable Cancers can be Targeted by HPV Vaccination
Meta-Analysis: Population-level Impact of HPV Vaccination Programs
Commentary on Twitter
NEW—Cervical cancer rates 87% lower in women offered vaccination against human papillomavirus (#HPV) between ages 12-13 than in previous generations, English study confirms.
First direct evidence of cervical cancer prevention using bivalent vaccine: https://t.co/HdQbGIKxZp pic.twitter.com/PMFermHGOv
— The Lancet (@TheLancet) November 3, 2021
ASCO Guideline Update: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy.
2 Nov, 2021 | 02:51h | UTC
ASCO Guideline: Management of immune-related adverse events in patients treated with Chimeric Antigen Receptor T-Cell Therapy.
2 Nov, 2021 | 02:47h | UTC
Review: Clinical management of pancreatic premalignant lesions.
31 Oct, 2021 | 19:56h | UTCClinical Management of Pancreatic Premalignant Lesions – Gastroenterology
Systematic Review: Management of cutaneous immune-related adverse events in patients with cancer treated with immune checkpoint inhibitors.
29 Oct, 2021 | 09:46h | UTCManagement of Cutaneous Immune-Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Review – JAMA Oncology (free for a limited period)
Systematic Review: Prophylactic antibiotics for preventing gram‐positive infections associated with long‐term central venous catheters in adults and children receiving treatment for cancer.
28 Oct, 2021 | 09:58h | UTC
RCT: Daratumumab, lenalidomide, and dexamethasone vs. lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma.
28 Oct, 2021 | 09:53h | UTC
RCT: A geriatric assessment–driven intervention can reduce chemotherapy-related toxic effects in older adults with cancer.
28 Oct, 2021 | 09:50h | UTCGeriatric Assessment–Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer: A Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Randomized trial with 604 older patients with cancer starting a new chemo regimen showed the incidence of grade 3 or higher chemo-related toxic effects was significantly lower in those who underwent a geriatric assessment-driven intervention https://t.co/QtOgmLDRU1
— JAMA Oncology (@JAMAOnc) October 1, 2021
RCT: Elective internal mammary node irradiation does not increase disease-free survival or overall survival in most women with node-positive breast cancer.
27 Oct, 2021 | 01:28h | UTCEffect of Elective Internal Mammary Node Irradiation on Disease-Free Survival in Women With Node-Positive Breast Cancer: A Randomized Phase 3 Clinical Trial – JAMA Oncology (free for a limited period)
Commentary: No Survival Benefit for Internal Mammary Node Irradiation in Breast Cancer — Women with medially or centrally located tumors may be candidates, however, says researcher – MedPage Today (free registration required)
Commentary on Twitter
Phase III randomized study evaluated the role of internal mammary node irradiation (IMNI) in node-positive #breastcancer. IMNI did not improve the DFS in unselected patients, but did improve DFS in patients with medially or centrally located tumors https://t.co/tw4ZrHn5wn pic.twitter.com/34ye3TR9MA
— JAMA Oncology (@JAMAOnc) October 25, 2021
Systematic Review: Virtual care in patients with cancer.
27 Oct, 2021 | 01:04h | UTCVirtual Care in Patients with Cancer: A Systematic Review – Current Oncology
RCT: Laparoscopic vs. open distal gastrectomy for locally advanced gastric cancer.
26 Oct, 2021 | 01:40h | UTCLaparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer: Five-Year Outcomes From the CLASS-01 Randomized Clinical Trial – JAMA Surgery (free for a limited period)
Commentary on Twitter
It is not clear whether laparoscopic (LDG) and open distal gastrectomy (ODG) produce similar long-term outcomes in advanced #gastriccancer. CLASS-01 trial firstly shows LDG results in similar 5-year OS compared to ODG in advanced gastric cancer https://t.co/uUBcLFeqsY
— JAMA Surgery (@JAMASurgery) October 20, 2021
Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study.
26 Oct, 2021 | 01:26h | UTCEditorial: QT prolongation and cancer therapeutics: a coming Tempest or Much Ado About Nothing?
Commentary: Anticancer Drug-Induced Life-Threatening Ventricular Arrhythmias – American College of Cardiology
Commentary on Twitter
Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization @WHO pharmacovigilance study https://t.co/ONAIFmOjZV #EHJ #ESCYoung #ventriculararrhythmias #cardiotwitter @ehj_ed @rladeiraslopes pic.twitter.com/t0fjoVy7fw
— European Society of Cardiology Journals (@ESC_Journals) August 23, 2021
NCCN Guideline: Cancer-Associated Venous Thromboembolic Disease.
21 Oct, 2021 | 10:06h | UTCRelated:
ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer
Review: venous and arterial thromboembolism in patients with cancer.
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.
21 Oct, 2021 | 09:48h | UTCPress release: metastatic breast cancer: new ESMO guideline with evidence-based recommendations – European Society of Medical Oncology
RCT: Nivolumab vs. placebo in patients with relapsed malignant mesothelioma.
21 Oct, 2021 | 09:46h | UTC
Commentary on Twitter
CONFIRM Trial: a phase III study demonstrated longer PFS and OS with Nivolumab compared with Placebo in patients with Pleural or Peritoneal Malignant Mesothelioma who have progressed following platinum-based chemotherapy @OncoAlert #LCSM https://t.co/jKoKXEXgpB
— Dipesh Uprety MD FACP (@DipeshUpretyMD) October 15, 2021
Cohort study: Acute urinary retention may be a clinical marker of occult prostate cancer and other urogenital, colorectal, and neurological cancers.
20 Oct, 2021 | 09:50h | UTCAcute urinary retention and risk of cancer: population based Danish cohort study – The BMJ
Commentary on Twitter
This study finds that a first diagnosis of acute urinary retention in patients aged 50 years or older was a clinical marker not only for prostate cancer but also for other urogenital cancers and colorectal and neurological cancershttps://t.co/0f1Z93cqR0 @dceaarhus
— The BMJ (@bmj_latest) October 19, 2021
Review: Wilms Tumor.
19 Oct, 2021 | 08:44h | UTCWilms tumour – Nature Reviews Disease Primers (free for a limited period)
Infographic: Wilms tumour
Commentary on Twitter
This is a schematic showing the timeline of key advances that established the modern clinical management of children with #Wilms tumour https://t.co/lT9ECVeuiZ pic.twitter.com/7KbMSo7qY3
— Nature Reviews Disease Primers (@DiseasePrimers) October 15, 2021
Opinion | Multi-cancer screening tests: communicating about risks should be prioritized.
19 Oct, 2021 | 08:49h | UTC
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomized trials.
15 Oct, 2021 | 02:07h | UTC
Commentary on Twitter
https://twitter.com/NicoleKuderer/status/1423002503138795521